Published in J Virol on January 20, 2010
Vaccine-induced CD8+ T cells control AIDS virus replication. Nature (2012) 1.78
Immune activation alters cellular and humoral responses to yellow fever 17D vaccine. J Clin Invest (2014) 1.12
Development of replication-competent viral vectors for HIV vaccine delivery. Curr Opin HIV AIDS (2013) 0.96
The influence of delivery vectors on HIV vaccine efficacy. Front Microbiol (2014) 0.92
GagCM9-specific CD8+ T cells expressing limited public TCR clonotypes do not suppress SIV replication in vivo. PLoS One (2011) 0.92
Advanced vaccine candidates for Lassa fever. Viruses (2012) 0.90
Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs. Vaccine (2010) 0.90
CD8+ T cells complement antibodies in protecting against yellow fever virus. J Immunol (2014) 0.87
Trivalent live attenuated influenza-simian immunodeficiency virus vaccines: efficacy and evolution of cytotoxic T lymphocyte escape in macaques. J Virol (2013) 0.86
Recombinant yellow fever viruses elicit CD8+ T cell responses and protective immunity against Trypanosoma cruzi. PLoS One (2013) 0.84
The live-attenuated yellow fever vaccine 17D induces broad and potent T cell responses against several viral proteins in Indian rhesus macaques--implications for recombinant vaccine design. Immunogenetics (2010) 0.83
Immunogenicity of seven new recombinant yellow fever viruses 17D expressing fragments of SIVmac239 Gag, Nef, and Vif in Indian rhesus macaques. PLoS One (2013) 0.83
Early IFN-gamma production after YF 17D vaccine virus immunization in mice and its association with adaptive immune responses. PLoS One (2013) 0.82
Vaccine-Induced Simian Immunodeficiency Virus-Specific CD8+ T-Cell Responses Focused on a Single Nef Epitope Select for Escape Variants Shortly after Infection. J Virol (2015) 0.80
Live attenuated rubella viral vectors stably express HIV and SIV vaccine antigens while reaching high titers. Vaccine (2012) 0.79
Live attenuated rubella vectors expressing SIV and HIV vaccine antigens replicate and elicit durable immune responses in rhesus macaques. Retrovirology (2013) 0.78
Dengue virus-specific CD4+ and CD8+ T lymphocytes target NS1, NS3 and NS5 in infected Indian rhesus macaques. Immunogenetics (2011) 0.78
Development of a PCR-Based Reverse Genetics System for an Attenuated Duck Tembusu Virus Strain. PLoS One (2016) 0.75
Future vaccines for a globalized world. Emerg Microbes Infect (2012) 0.75
Improved genetic stability of recombinant yellow fever 17D virus expressing a lentiviral Gag gene fragment. Virology (2014) 0.75
T Cell-Mediated Immunity towards Yellow Fever Virus and Useful Animal Models. Viruses (2017) 0.75
Development of a Recombinant Yellow Fever Vector Expressing a HIV Clade C Founder Envelope gp120. J Virol Methods (2017) 0.75
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet (2008) 19.65
HIV vaccine design and the neutralizing antibody problem. Nat Immunol (2004) 9.48
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet (2008) 8.37
Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med (2009) 7.33
Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature (2008) 6.17
Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity (2008) 5.22
Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol (2006) 4.68
Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol (2007) 4.54
Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med (2008) 3.35
Stimulation history dictates memory CD8 T cell phenotype: implications for prime-boost vaccination. J Immunol (2006) 3.29
Advances in tuberculosis vaccine strategies. Nat Rev Microbiol (2006) 2.75
Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J Virol (2008) 2.66
Macaques vaccinated with live-attenuated SIV control replication of heterologous virus. J Exp Med (2008) 2.59
Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge. J Virol (2009) 2.38
Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J Immunol (2000) 2.29
Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239. J Virol (2003) 2.14
Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. J Virol (2000) 2.09
Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure. J Virol (1998) 1.98
A live, attenuated recombinant West Nile virus vaccine. Proc Natl Acad Sci U S A (2006) 1.72
Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication. J Virol (2002) 1.67
Yellow fever 17D as a vaccine vector for microbial CTL epitopes: protection in a rodent malaria model. J Exp Med (2005) 1.46
Effects of cytotoxic T lymphocytes (CTL) directed against a single simian immunodeficiency virus (SIV) Gag CTL epitope on the course of SIVmac239 infection. J Virol (2002) 1.44
A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J Infect Dis (2008) 1.39
Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques. J Virol (2005) 1.36
Recombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases. J Virol (2000) 1.35
Infection with "escaped" virus variants impairs control of simian immunodeficiency virus SIVmac239 replication in Mamu-B*08-positive macaques. J Virol (2009) 1.33
Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine (2008) 1.24
Tuberculosis vaccine research: the impact of immunology. Curr Opin Immunol (2009) 1.22
Construction and characterization of recombinant flaviviruses bearing insertions between E and NS1 genes. Virol J (2007) 1.20
Vaccine-induced, simian immunodeficiency virus-specific CD8+ T cells reduce virus replication but do not protect from simian immunodeficiency virus disease progression. J Immunol (2009) 1.19
Vaccination of macaques with SIV immunogens delivered by Venezuelan equine encephalitis virus replicon particle vectors followed by a mucosal challenge with SIVsmE660. Vaccine (2005) 1.14
Surface expression of an immunodominant malaria protein B cell epitope by yellow fever virus. J Mol Biol (2002) 1.08
A computational resource for the prediction of peptide binding to Indian rhesus macaque MHC class I molecules. Vaccine (2005) 1.08
Effective simian immunodeficiency virus-specific CD8+ T cells lack an easily detectable, shared characteristic. J Virol (2009) 1.01
Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development. Expert Opin Biol Ther (2008) 1.00
Limited replication of yellow fever 17DD and 17D-Dengue recombinant viruses in rhesus monkeys. An Acad Bras Cienc (2008) 0.84
Protective immunity elicited by rBCG vaccines. Dev Biol Stand (1994) 0.77
Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat Med (2004) 6.33
Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity (2008) 5.86
Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog (2009) 5.82
Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature (2012) 5.49
Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science (2004) 5.31
HIV and SIV CTL escape: implications for vaccine design. Nat Rev Immunol (2004) 5.18
Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat Rev Immunol (2008) 5.17
Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nat Med (2002) 5.17
Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag. J Virol (2005) 4.78
Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol (2006) 4.68
The high-frequency major histocompatibility complex class I allele Mamu-B*17 is associated with control of simian immunodeficiency virus SIVmac239 replication. J Virol (2006) 4.26
HIV vaccine research: the way forward. Science (2008) 3.86
Subdominant CD8+ T-cell responses are involved in durable control of AIDS virus replication. J Virol (2007) 3.85
Expression of the major histocompatibility complex class I molecule Mamu-A*01 is associated with control of simian immunodeficiency virus SIVmac239 replication. J Virol (2003) 3.64
Mamu-B*08-positive macaques control simian immunodeficiency virus replication. J Virol (2007) 3.61
Gag-specific CD8+ T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J Immunol (2007) 3.59
Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci U S A (2012) 3.30
Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science (2013) 3.27
Immune clearance of highly pathogenic SIV infection. Nature (2013) 3.15
Premature induction of an immunosuppressive regulatory T cell response during acute simian immunodeficiency virus infection. J Infect Dis (2006) 3.04
Rapid viral escape at an immunodominant simian-human immunodeficiency virus cytotoxic T-lymphocyte epitope exacts a dramatic fitness cost. J Virol (2005) 3.03
Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J Exp Med (2004) 2.99
Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications. Immunogenetics (2005) 2.99
Molecular correlates of primate nuclear transfer failures. Science (2003) 2.79
Advances in tuberculosis vaccine strategies. Nat Rev Microbiol (2006) 2.75
HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol (2006) 2.72
Extraepitopic compensatory substitutions partially restore fitness to simian immunodeficiency virus variants that escape from an immunodominant cytotoxic-T-lymphocyte response. J Virol (2004) 2.71
Macaques vaccinated with live-attenuated SIV control replication of heterologous virus. J Exp Med (2008) 2.59
Dominance of CD8 responses specific for epitopes bound by a single major histocompatibility complex class I molecule during the acute phase of viral infection. J Virol (2002) 2.50
Unparalleled complexity of the MHC class I region in rhesus macaques. Proc Natl Acad Sci U S A (2005) 2.41
CD8+ T-lymphocyte response to major immunodominant epitopes after vaginal exposure to simian immunodeficiency virus: too late and too little. J Virol (2005) 2.41
Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge. J Virol (2009) 2.38
A dominant role for CD8+-T-lymphocyte selection in simian immunodeficiency virus sequence variation. J Virol (2004) 2.33
Molecular typing of major histocompatibility complex class I alleles in the Indian rhesus macaque which restrict SIV CD8+ T cell epitopes. Immunogenetics (2007) 2.14
Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239. J Virol (2003) 2.14
The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults. Am J Respir Crit Care Med (2010) 2.03
Public clonotype usage identifies protective Gag-specific CD8+ T cell responses in SIV infection. J Exp Med (2009) 2.03
Characterization of the peptide-binding specificity of Mamu-B*17 and identification of Mamu-B*17-restricted epitopes derived from simian immunodeficiency virus proteins. J Immunol (2002) 1.97
Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon. Infect Immun (2007) 1.85
Unusually high frequency MHC class I alleles in Mauritian origin cynomolgus macaques. J Immunol (2005) 1.83
Identification of seventeen new simian immunodeficiency virus-derived CD8+ T cell epitopes restricted by the high frequency molecule, Mamu-A*02, and potential escape from CTL recognition. J Immunol (2004) 1.81
The antiviral efficacy of simian immunodeficiency virus-specific CD8+ T cells is unrelated to epitope specificity and is abrogated by viral escape. J Virol (2006) 1.78
Vaccine-induced CD8+ T cells control AIDS virus replication. Nature (2012) 1.78
Patterns of CD8+ immunodominance may influence the ability of Mamu-B*08-positive macaques to naturally control simian immunodeficiency virus SIVmac239 replication. J Virol (2007) 1.78
Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication. J Virol (2002) 1.67
Macaques vaccinated with simian immunodeficiency virus SIVmac239Delta nef delay acquisition and control replication after repeated low-dose heterologous SIV challenge. J Virol (2010) 1.66
Technical failure of medial patellofemoral ligament reconstruction. Arthroscopy (2011) 1.58
Two MHC class I molecules associated with elite control of immunodeficiency virus replication, Mamu-B*08 and HLA-B*2705, bind peptides with sequence similarity. J Immunol (2009) 1.57
A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX in healthy children. Vaccine (2002) 1.56
Analysis of pigtail macaque major histocompatibility complex class I molecules presenting immunodominant simian immunodeficiency virus epitopes. J Virol (2005) 1.52
Accurate early infant HIV diagnosis in primary health clinics using a point-of-care nucleic acid test. J Acquir Immune Defic Syndr (2014) 1.52
CD8+ T cells from SIV elite controller macaques recognize Mamu-B*08-bound epitopes and select for widespread viral variation. PLoS One (2007) 1.52
Gag- and Nef-specific CD4+ T cells recognize and inhibit SIV replication in infected macrophages early after infection. Proc Natl Acad Sci U S A (2009) 1.51